舒尼替尼2/1方案与4/2方案治疗转移性肾癌的疗效及对不良反应耐受性的对比分析

潘秀武; 干思舜; 崔心刚; 徐丹枫; 黄海; 黄毅

doi:10.13201/j.issn.1001-1420.2015.03.008

舒尼替尼2/1方案与4/2方案治疗转移性肾癌的疗效及对不良反应耐受性的对比分析

- 第二军医大学附属长征医院泌尿外科(上海, 200003)

详细信息

通讯作者: 崔心刚,E-mail:xingangcui@126.com

中图分类号: R737.11

收稿日期: 2014-11-01

Efficacy and tolerability of two weeks on and one week off schedule of sunitinib versus standard four weeks on and two weeks off schedule for metastatic renal cell carcinoma

- Department of Urology, Changzheng Hospital of Second Military Medical University, Shanghai, 200003, China

More Information

Corresponding author: CUI Xingang, E-mail: xingangcui@126.com

Received Date: 01 November 2014

摘要

摘要: 目的:对比分析舒尼替尼2/1方案与4/2方案治疗转移性肾癌的疗效及其对不良反应的耐受性。方法:2009年1月~2013年1月采用舒尼替尼2/1方案(每天50 mg,服用2周,停用1周)和4/2方案(每天50 mg,服用4周,停用2周)治疗转移性肾癌患者56例,其中接受2/1方案治疗者18例,4/2方案治疗者38例。第1个疗程每周随访1次,此后每3周随访1次,并进行有效性及安全性评价,随访时间至少1年,统计分析比较两组患者疗效及其对不良反应的耐受性。结果:采用舒尼替尼治疗转移性肾癌患者12个月的效果评价,两种方案差异无统计学意义;但在部分药物不良反应中,如手足综合征、乏力、白细胞减少、腹泻中,2/1方案明显优于4/2方案(手足综合征:P=0.004;乏力:P=0.015;白细胞减少:P=0.013;腹泻:P=0.022)。结论:舒尼替尼2/1方案治疗转移性肾癌与4/2方案相比疗效相似,但不良反应发生率低。
- 肾肿瘤 /
- 肾部分切除术 /
- R.E.N.A.L.评分 /
- PADUA评分 /
- 预后
Abstract: Objective:To compare the efficacy and tolerability between 2/1 sunitinib schedule and standard 4/2 schedule in patients with metastatic renal cell carcinoma.Method:A retrospective analysis of patients with metastatic renal cell carcinoma treated with sunitinib was carried out from January 2009 to January 2013 in our hospital. Dosing schedules of sunitinib included schedule 2/1 (50 mg/day, two weeks on and one week off) and schedule 4/2 (50 mg/day, four weeks on and two weeks off). Schedule 2/1 was performed in 18 patients, and schedule 4/2 was carried out in 38 patients. We evaluated and compared the efficacy and safety between two schedules. The follow-up data were collected once a week at the first course and then every three weeks in the following courses, and the duration of follow-up of each patient was more than one year. Statistical analysis was carried out to compare the efficacy and tolerability between two groups.Result:No statistical significance was found in the results of 12-month therapeutic evaluation of patients with metastatic renal cell carcinoma between two schedules. The rate of adverse events of hand-foot syndrome, fatigue, leukocytopenia and diarrhoea in patients treated with sunitinib was significantly lower in the schedule 2/1 group than in the schedule 4/2 group (hand-foot syndrome: P=0.004; fatigue: P=0.015; leukocytopenia: P=0.013; diarrhoea: P=0.022). However, there was no statistical difference in other adverse events caused by sunitinib between two schedules.Conclusion:Schedule 2/1 of sunitinib in patients with metastatic renal cell carcinoma was associated with lower adverse event rate and similar efficacy compared with schedule 4/2.
- metastatic renal cell carcinoma /
- sunitinib /
- schedule 2/1 /
- schedule 4/2 /

HTML全文

参考文献(17)

[1]	赫捷,赵平,陈万青主编. 2012中国肿瘤登记年报[M]. 北京:军事医学科学出版社,2012:118-153.
[2]	Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[3]	Hutson T E, Figlin R A, Kuhn J G, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies[J]. Oncologist, 2008, 13(10): 1084-1096.
[4]	Robert F, Sandler A, Schiller J H, et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study[J]. Cancer Chemoth Pharm, 2010, 66(4): 669-680.
[5]	Britten C D, Kabbinavar F, Hecht J R, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period[J]. Cancer Chemoth Pharm, 2008, 61(3): 515-524.
[6]	Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[7]	许崇安,邢丽丽,王小杰,等. 靶向药物治疗晚期肾癌的meta分析[J]. 现代肿瘤医学,2012,20(12):2582-2588.
[8]	Motzer R J, Hutson T E, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27(22): 3584-3590.
[9]	Motzer R J, Rini B I, Bukowski R M, et al. Sunitinib in patients with metastatic renal cell carcinoma[J]. JAMA, 2006, 295(21): 2516-2524.
[10]	Mendel D B, Laird A D, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003, 9(1): 327-337.
[11]	Gore M E, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial[J]. Lancet Oncol, 2009, 10(8): 757-763.
[12]	施国海,叶定伟,姚旭东,等. 舒尼替尼治疗转移性肾癌的近期疗效及耐受性[J]. 中华泌尿外科杂志,2011,32(6):423-426.
[13]	Kondo T, Takagi T, Kobayashi H, et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off [J]. Jpn J Clin Oncol, 2014, 44(3): 270-277.
[14]	Najjar Y G, Mittal K, Elson P, et al. A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma[J]. Eur J Cancer, 2014, 50(6): 1084-1089.
[15]	吴翔,李学松,黄立华,等. 舒尼替尼治疗转移性肾癌的疗效和安全性分析:单中心37例总结[J]. 中华泌尿外科杂志, 2011, 32(4): 278-281.
[16]	Sweeney C J, Chiorean E G, Verschraegen C F, et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors[J]. J Clin Oncol, 2010, 28(29): 4513-4520.
[17]	Zhou A. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience[J]. Asia Pac J Clin Oncol, 2012, 8(2): 132-144.